Empowering BioLegacy to Lead Innovation in Combating the Opioid Epidemic Through Advanced Manufacturing and ResearchVANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC: BLEG), a pioneering biotechnology company dedicated to revolutionizing addiction treatment and harm reduction solutions, today announced that its subsidiary, BioLegacy Evaluative Group, has acquired a 22,000-square-foot commercial property in Vancouver, Canada. This strategic acquisition estab ...

New York, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has initiated coverage of BioCorRx®, Inc. (OTCQB: BICX). The in-depth initiation report includes detailed information on the BioCorRx®, Inc. business model, services, industry, valuation, management, and risks. The full research report is available below. BioCorRx® Inc. Initiation of Coverage  Highlights from the report include:                                    ...

Acquisition Poised to Accelerate Life-Saving Interventions, Combining Academic Excellence with Real-World Innovation to Address Global Addiction Crises and Unlock Multi-Billion Market OpportunitiesVANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC: BLEG), a leading diversified holdings company dedicated to pioneering health and wellness solutions, today announced a groundbreaking strategic partnership between its wholly-owned subsidiary, Bio-Legacy Evaluative ...

Core Insights - Adial Pharmaceuticals has made significant progress in the first quarter of 2025, particularly in advancing its lead investigational drug AD04 for Alcohol Use Disorder (AUD) [2] - The company successfully completed a pharmacokinetics bridging study, confirming favorable bioavailability of AD04, and has begun manufacturing clinical trial supplies [2] - Regulatory alignment with the FDA has been achieved, supporting a streamlined path for the upcoming Phase 3 clinical trial [2] - Adial has strengthened its intellectual property portfolio with multiple granted patents related to AD04 [5] Financial Results - As of March 31, 2025, cash and cash equivalents were $2.4 million, down from $3.8 million as of December 31, 2024 [12] - Research and development expenses increased by approximately $293 thousand (65%) compared to the same period in 2024, driven by increased CMC expenses and consulting [12] - General and administrative expenses rose by approximately $129 thousand (9%) due to higher compensation and consulting [12] - The net loss for the first quarter of 2025 was $2.2 million, a decrease from a net loss of $6.5 million in the same quarter of 2024 [12] Strategic Developments - Adial received a six-figure milestone payment from Adovate, LLC, following the start of a Phase 1 clinical trial for an asthma compound [3] - The company is eligible for over $50 million in commercial milestone payments and an additional $11 million in development and approval milestone payments for the first three compounds [4] - Adial retains over a 10% equity stake in Adovate, allowing participation in the long-term upside as the asthma candidate progresses [4] Intellectual Property - A new patent was issued covering the administration of AD04 as a precision medicine approach for patients with specific genetic markers [5] Future Outlook - The company is preparing for an End of Phase 2 meeting with the FDA in July to finalize the Phase 3 trial design [2][13] - There is confidence in advancing AD04 through late-stage development, with potential applications for other addictive disorders such as Opioid Use Disorder, gambling, and obesity [9][13]

Core Insights - Adial Pharmaceuticals has achieved a milestone by receiving a six-figure payment from Adovate, LLC, following the initiation of a Phase 1 clinical trial for ADO-5030, a novel asthma therapy targeting a significant market with unmet medical needs [1][2][3] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for addiction and related disorders, with its lead product AD04 targeting Alcohol Use Disorder (AUD) [4] Financial Aspects - Under the agreement with Adovate, Adial is eligible for over $50 million in commercial milestone payments and an additional $11 million in development and approval milestone payments per compound, totaling up to $83 million for the first three compounds if milestones are achieved [3][7] - Adial retains a significant equity stake of over 10% in Adovate, allowing participation in the long-term upside as the asthma candidate progresses [3][7] Clinical Development - The ongoing Phase 1 study for ADO-5030 is a Single Ascending Dose (SAD) trial aimed at evaluating safety, tolerability, and pharmacokinetics in healthy volunteers, with the potential to shift the treatment paradigm for asthma patients globally [2][3]